Prescription Use: TRAUMASTAT Hemostatic Wound Dressing is intended for external temporary use to control moderate to severe bleeding. Over the Counter Use (OTC): TRAUMASTAT Hemostatic Wound Dressing is intended for temporary external use to stop bleeding of superficial wounds, minor cuts, and abrasions.
Device Story
TRAUMASTAT is a non-woven hemostatic wound dressing; composed of porous polyethylene fibers filled with precipitated silica and coated with chitosan (poly-N-acetylglucosamine). Device acts as a physical barrier and hemostatic agent to arrest bleeding. Provided in various dimensions; 3mm thickness; 0.15 g/cc density. Hermetically sealed in poly foil pouch; electron beam sterilized. Used in clinical or home settings for temporary external bleeding control. Applied by clinicians or patients to wounds; facilitates hemostasis through material properties. Benefits include rapid bleeding control for traumatic or minor injuries.
Clinical Evidence
No human clinical trials provided. Safety established via in-vitro biocompatibility testing (cytotoxicity, sensitization, skin irritation) per ISO 10993. Effectiveness demonstrated via in-vivo animal testing using swine models to evaluate hemostatic properties in induced severe bleeding traumatic wounds.
Technological Characteristics
Non-woven substrate of porous polyethylene fibers filled with precipitated silica; coated with chitosan (poly-N-acetylglucosamine). Fiber diameter 20-100 micrometers; 3mm thickness; 0.15 g/cc density. Sterilization via electron beam. Hermetically sealed in poly foil pouch.
Indications for Use
Indicated for external temporary control of moderate to severe bleeding (prescription) or superficial wounds, minor cuts, and abrasions (OTC).
Regulatory Classification
Identification
To temporarily control bleeding and cover external wounds.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size, also in blue.
July 28, 2023
Ore-Medix, LLC c/o International Regulatory Consultants, L.C. Donald F. Grabarz Managing Director 7651 South 700 West, Suite 105 Midvale, Utah 84047
Re: K080648
Trade/Device Name: TRAUMASTAT™ Hemostatic Wound Dressing Regulatory Class: Unclassified Product Code: QSY
Dear Donald F. Grabarz:
The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated May 7, 2008. Specifically, FDA is updating this SE Letter because FDA has better categorized your device technology under product code QSY.
Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Julie Morabito, OHT4: Office of Surgical and Infection Control Devices, 240-402-3839, Julie.Morabito@fda.hhs.gov.
> Sincerely, Julie A. Morabito -S
Julie Morabito, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services, USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES, USA" arranged around the perimeter. Inside the circle is a stylized emblem resembling an eagle or bird-like figure with flowing lines, representing the department's mission related to health and human services.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
# MAY - 7 2008
Ore-Medix, LLC % International Regulatory Consultants, LC Mr. Donald F. Grabarz Managing Director 7651 South 700 West, Suite 105 Midvale, Utah 84047
Re: K080648
Trade/Device Name: TRAUMASTAT™ Hemostatic Wound Dressing Regulatory Class: Unclassified Product Code: FRO Dated: April 21, 2008 Received: April 22, 2008
Dear Mr. Grabarz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{2}------------------------------------------------
Page 2 - Mr. Donald F. Grabarz
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Mark N. Millman
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Page 1 of 1
## Indications for Use Statement
510(k) Number: K080648
Device Name: TRAUMASTAT™ Hemostatic Wound Dressing
Indications For Use:
Prescription Use:
TRAUMASTAT™ Hemostatic Wound Dressing is intended for external temporary use to control moderate to severe blocding.
Over the Counter Use:
TRAUMASTAT™ Hemostatic Wound Dressing is intended for external temporary use to stop bleeding of superficial wounds, minor cuts, and abrasions.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use X (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Nikhil al for an
Sign Off
Division of General, Restorative and Neurological Devices
**510(k) Number** K080648
{4}------------------------------------------------
K080648
page 1 of 2
#### 510(k) SUMMARY 5.0
#### TRAUMASTAT™ Hemostatic Wound Dressing
| | MAY - 7 2008 |
|------------------------------|-------------------------------------------------------------------------------------------------------|
| Name and Address of Sponsor: | Ore-Medix, LLC<br>3080 25th Street SE<br>Salem, OR 97302 |
| Submitted by: | International Regulatory Consultants, L.C.<br>7651 S. 700 West, Suite 105<br>Salt Lake City, UT 84047 |
#### Description of Device:
TRAUMASTAT™ Hemostatic Wound Dressing is a unique non-woven substrate comprised of porous polyethylene fibers highly filled with precipitated silica. This substrate is coated with chitosan, manufactured from ChitoClear™, a material consisting of the cellulosic polymer, poly-N-acctylglucosamine which is generally recognized as safe in accordance with 21 CFR 170,30. Each fiber of the wound dressing is approximately 20 to 100 micrometers in diameter. The wound dressing is provided in multiple lengths and widths to accommodate varying clinical situations as appropriate for its intended use. The dressing thickness is approximately 3 mm with an average density of approximately 0.15 gram/cc.
TRAUMATAT Hemostatic Wound Dressing is hermetically sealed in a poly foil pouch and electron beam sterilized.
### Intended Use of Device:
Prescription Use: TRAUMASTAT Hemostatic Wound Dressing is intended for external temporary use to control moderate to severe bleeding.
Over the Counter Use (OTC): TRAUMASTAT Hemostatic Wound Dressing is intended for temporary external use to stop bleeding of superficial wounds, minor cuts, and abrasions.
#### Substantially Equivalent Predicate/Comparative Devices:
The TRAUMASTAT Hemostatic Wound Dressing is substantially equivalent to the following commercially available devices.
| Product Name: | ChitoFlex™ Hemostatic Dressing |
|----------------|--------------------------------|
| Manufacturer: | HemCon Inc. |
| 510(k) Number: | K071519 |
| Product Name: | QuikClot® eX™ |
| Manufacturer: | Z-Medica Corporation |
| 510(k) Number: | K072474 |
{5}------------------------------------------------
### Safety and Effectiveness:
Image /page/5/Picture/1 description: The image shows the text "K080648 page 2 of 2". The text appears to be handwritten. The first line contains a series of alphanumeric characters, while the second line indicates that it is page 2 of 2.
Based on in-vitro biocompatibility testing in accordance with FDA requirements and ISO 10993 for external communicating, breached surface blood contact devices for cytotoxicity, sensitization and skin irritation, the TRAUMASTAT Hemostatic Wound Dressing is concluded to be safe for its intended use. In-vivo animal testing conducted on swine models demonstrates the effectiveness of the hemostatic properties in arresting scvcrely bleeding induced traumatic wounds.
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.